supported by the Beijing Natural Science Foundation(No.L222128);Beijing Institute of Technology Research Fund Program for Young Scholars(No.XSQD-202121010);National Natural Science Foundation of China(No.81961138009)。
Insufficient intratumoral retention of nanomedicines remains the major challenge for broad implementation in clinical sets.Herein,we proposed a legumain-triggered aggregable gold nanoparticle(GNP)delivery platform(GNP...
supported by Zhejiang Provincial Natural Science Foundation of China(No.D19H300001).
Compressed blood and intratumoral lymphatic vessels induced by proliferated tumor cells and elevated interstitial fluid pressure produce regional hypoxic and necrotic region within tumors,which severely reduced the ac...
support of National Key Research and Development Program of China(2021YFE0103100,China);National Natural Science Foundation of China of China(81925035,81673382,and 81521005,China);National Special Project for Significant New Drugs Development(2018ZX09711002-010-002,China);Shanghai SciTech Innovation Initiative(19431903100,18430740800,China);Shanghai Collaborative Innovation Group of Early Diagnosis and Precise Treatment of Hemangiomas and Vascular Malformations(SSMU-ZDCX20180701,China);Chinese Pharmaceutical Association-Yiling Pharm Joint Grants(CPAYLJ201901,China)for the support。
An essential step for cancer vaccination is to break the immunosuppression and elicit a tumor-specific immunity.A major hurdle against cancer therapeutic vaccination is the insufficient immune stimulation of the cance...
This work was financially sponsored by the National Natural Science Foundation of China(Nos.51773152);the Science and Technology Plans of Tianjin(15JCYBJC17900);the Natural Science Foundation of Tianjin(18JCYBJC17500).
Brain barrier is both a protective permeability hurdle and a limitation site where therapeutic agents are excluded to enter the target region.Designing drug vehicle to overcome this notorious barrier bottle is challen...
supported by the National Natural Science Foundation of China(81671375,91949116 and 81873807);Innovative Research Team of High-level Local Universities in Shanghai,China.
Background:Currently,there is no cure for Alzheimer's disease(AD).Therapeutics that can modify the early stage of AD are urgently needed.Recent studies have shown that the pathogenesis of AD is closely regulated by an...